Dr. Do on the Assessment of Tumor Response in Liver Cancer

Richard Kinh Gian Do, MD, PhD
Published: Sunday, Sep 11, 2016



Richard Kinh Gian Do, MD, PhD, radiologist, Memorial Sloan Kettering Cancer Center, discusses the assessment of tumor response in hepatocellular carcinoma (HCC).

While tumor shrinkage is the standard by which oncologists assess how well a therapy is working for a patient, investigators are currently looking at alternative ways of establishing the benefit of an agent from a biological perspective. Assessing therapeutic responses can be a bit different when it comes to treating patients with HCC, explains Do.

Given the fact that HCC is vascular, oncologists can measure how a tumor enhances and how it devascularizes after treatment. As a result, it may be possible to detect an earlier difference in therapeutic changes or benefits. The real controversy, says Do, lies in determining the best way to measure both tumor size and tumor enhancement in patients with HCC.

<<< View more from the 2016 International Liver Cancer Association Annual Conference



Richard Kinh Gian Do, MD, PhD, radiologist, Memorial Sloan Kettering Cancer Center, discusses the assessment of tumor response in hepatocellular carcinoma (HCC).

While tumor shrinkage is the standard by which oncologists assess how well a therapy is working for a patient, investigators are currently looking at alternative ways of establishing the benefit of an agent from a biological perspective. Assessing therapeutic responses can be a bit different when it comes to treating patients with HCC, explains Do.

Given the fact that HCC is vascular, oncologists can measure how a tumor enhances and how it devascularizes after treatment. As a result, it may be possible to detect an earlier difference in therapeutic changes or benefits. The real controversy, says Do, lies in determining the best way to measure both tumor size and tumor enhancement in patients with HCC.

<<< View more from the 2016 International Liver Cancer Association Annual Conference


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x